Genmab A (GMAB) Total Liabilities (2019 - 2026)
Genmab A's (GMAB) quarterly Total Liabilities came in at $6.7 billion in Q1 2026, up 1.64% YoY from $6.6 billion in Q1 2025, and down 4.73% on a QoQ basis from $7.0 billion in Q4 2025.
Genmab A (GMAB) Total Liabilities (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Total Liabilities data on file, last reported at $6.7 billion in Q1 2026.
- Quarterly Total Liabilities rose 1.64% year-over-year to $6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (up 1.64% YoY) and the FY2025 annual result came in at $7.0 billion, up 450.2% from the prior year.
- Total Liabilities eased to $6.7 billion in Q1 2026, from $7.0 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $7.0 billion in Q4 2025 to a low of $545.0 million in Q4 2023.
- A 4-year average of $3.5 billion and a median of $1.3 billion in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2025 — Total Liabilities jumped 450.2% — and 2026, when it advanced 1.64%.
- Tracing GMAB's Total Liabilities over 4 years: stood at $545.0 million in 2023, then jumped by 134.31% to $1.3 billion in 2024, then jumped by 450.2% to $7.0 billion in 2025, then dropped by 4.73% to $6.7 billion in 2026.
- The last three Total Liabilities figures came in at $6.7 billion (Q1 2026), $7.0 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 6.56 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.56 Bn |
| Mar 31, 2026 | 6.69 Bn |
| Dec 31, 2025 | 7.03 Bn |
| Sep 30, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1.16 Bn |
| Mar 31, 2025 | 6.59 Bn |
| Dec 31, 2024 | 1.28 Bn |
| Dec 31, 2023 | 545.00 Mn |
| Sep 30, 2020 | 3,045,000.00 Bn |
| Dec 31, 2019 | 1,096,000.00 Bn |
| Sep 30, 2019 | 815.67 Mn |